If we will provide a better understanding of underlying mechanisms of myelomagenesis, then we will be able to reach are goals to (1) define high-risk precursor disease patinets, and to (2) delay and prevent development of multiple myeloma. For example, in 2010, we opened a treatment study for smoldering, using a novel treatment approach modality (a monoclonal antibody which targets natural killer cells, which in turn will cause anti-myeloma effect). In 2011, we have developed the second generation of treatment studies based on our generated data from the molecular profiling studies we are doing in parallel. If we will be able to goals to delay/prevent myeloma, it will have a major impact on the clinical management and outcome for these patients in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011352-04
Application #
8763472
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2013
Total Cost
$1,195,259
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code